Research progress in immune checkpoint molecule TIGIT in hematologic malignant diseases
10.3760/cma.j.cn112309-20240129-00038
- VernacularTitle:免疫检查点分子TIGIT在血液系统恶性疾病中的研究进展
- Author:
Huihui AN
1
;
Tao WU
1
;
Yunyun LI
1
Author Information
1. 中国人民解放军联勤保障部队第九四〇医院血液病内科，兰州 730050
- Publication Type:Journal Article
- Keywords:
Immune checkpoints;
TIGIT;
Antigen-presenting cells;
Programmed death-1
- From:
Chinese Journal of Microbiology and Immunology
2025;45(5):448-452
- CountryChina
- Language:Chinese
-
Abstract:
The occurrence of malignant tumors is related to immune evasion caused by the upregulation of immune checkpoint inhibitory receptors. T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is a novel immune checkpoint receptor with remarkable prospects in the treatment of hematologic malignancies. In addition to acting on T cells, TIGIT can also participate in the development of hematologic malignant diseases by regulating antigen-presenting cells, but the specific mechanism of action is still unclear. This review summarizes the latest research progress in the molecular structure, inhibitory function, immunomodulatory effect of TIGIT and the mechanism by which TIGIT modulates antigen-presenting cells to participate in the pathogenesis of malignant hematological diseases, so as to provide a theoretical basis for an in-depth understanding of the immune regulatory role of TIGIT in hematologic malignant diseases.
